† Seroprotection rates at ≥ 0.10 IU/mL and booster response rates to ADACEL vaccine were non-inferior to Td vaccine (upper limit of the 95% CI on the difference for Td vaccine minus ADACEL vaccine <10%).

† Seroprotection rates at ≥1.0 IU/mL were not designed as a primary endpoint, however ADACEL vaccine met non-inferiority criteria (upper limit of the 95% CI on the difference for Td vaccine minus ADACEL vaccine <10%) at this level.

Table 3: Ratio of Pertussis Antibody Geometric Mean Concentrations (GMCs)† Observed One Month After a Dose of ADACEL Vaccine in Adolescents and Adults Compared with Those Observed in Infants One Month Following Three Doses at 2, 4 and 6 Months of Age in an Efficacy Trial with DAPTACEL Vaccine

	Adolescents ADACEL/DAPTACEL GMC Ratio* (95% CIs)	Adults ADACEL/DAPTACEL GMC Ratio* (95% CIs)
Anti-PT	3.6 (2.8, 4.5)†	2.1 (1.6, 2.7)†
Anti-FHA	5.4 (4.5, 6.5)†	4.8 (3.9, 5.9)†
Anti-PRN	3.2 (2.5, 4.1)†	3.2 (2.3, 4.4)†
Anti-FIM	5.3 (3.9, 7.1)†	2.5 (1.8, 3.5)†

* The ratios of GMC were determined for adolescents compared to infants, as well as for adults compared to infants.

† GMC following ADACEL vaccine was non-inferior to GMC following DAPTACEL vaccine (lower limit of 95% CI on the ratio of GMC for ADACEL vaccine divided by DAPTACEL vaccine >0.67).

† Antibody GMCs, measured in arbitrary ELISA units were calculated separately for infants, adolescents and adults.

	Adolescents N = 524 % (95% CI)	Adults N = 739 % (95% CI)	Pre-defined Acceptable Rates* %†
Anti-PT	92 (89.3, 94.2)	84.4 (81.6, 87.0)	81.2
Anti-FHA	85.6 (82.3, 88.4)	82.7 (79.8, 85.3)	77.6
Anti-PRN	94.5 (92.2, 96.3)	93.8 (91.8, 95.4)	86.4
Anti-FIM	94.9 (92.6, 96.6)	85.9 (83.2, 88.4)	82.4

* The acceptable response rate for each antigen was defined as the lower limit of the 95% CI for the rate being no more than 10% lower than the response rate observed in previous clinical trials.